Nava Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
Series B
- Investors
-
7
Nava Therapeutics General Information
Description
Operator of a biotechnology company intended to develop next-generation RNA therapeutics by creating advanced lipid nanoparticle delivery technology. The company's proprietary platform is designed to overcome challenges in RNA medicine, allowing targeted and safe delivery to be administered at clinically relevant doses while minimizing off-target effects, enabling healthcare industry to expand the potential of RNA-based treatments for serious diseases.
Contact Information
Website
www.navatx.comCorporate Office
- 600/700 One Kendall Square
- Suite B
- Cambridge, MA 02139
- United States
Corporate Office
- 600/700 One Kendall Square
- Suite B
- Cambridge, MA 02139
- United States
Nava Therapeutics Timeline
Nava Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 16-Jul-2026 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 24-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | $10M | $10M | Completed | Pre-Clinical Trials |
Nava Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nava Therapeutics Patents
Nava Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026207228-A2 | Novel lipids, lipid compositions containing thereof, and methods of using thereof | Pending | 27-Mar-2025 | ||
| WO-2025217298-A1 | Novel lipids containing diketopiperazine core, lipid nanoparticle containing thereof, and methods of using thereof | Pending | 10-Apr-2024 | ||
| WO-2025217299-A1 | Novel lipids containing diketopiperazine core, lipid nanoparticle containing thereof, and methods of using thereof | Pending | 10-Apr-2024 | C07D241/08 |
Nava Therapeutics Signals
Nava Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Andreessen Horowitz | Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| Readout Capital | Hedge Fund | Minority |
Nava Therapeutics FAQs
-
When was Nava Therapeutics founded?
Nava Therapeutics was founded in 2022.
-
Where is Nava Therapeutics headquartered?
Nava Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Nava Therapeutics?
Nava Therapeutics has 37 total employees.
-
What industry is Nava Therapeutics in?
Nava Therapeutics’s primary industry is Drug Discovery.
-
Is Nava Therapeutics a private or public company?
Nava Therapeutics is a Private company.
-
What is Nava Therapeutics’s current revenue?
The current revenue for Nava Therapeutics is .
-
How much funding has Nava Therapeutics raised over time?
Nava Therapeutics has raised $89M.
-
Who are Nava Therapeutics’s investors?
Alexandria Venture Investments, Andreessen Horowitz, F-Prime, GV, and Readout Capital are 5 of 7 investors who have invested in Nava Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process